T
Tim Heise
Researcher at University of Padua
Publications - 208
Citations - 11201
Tim Heise is an academic researcher from University of Padua. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 52, co-authored 188 publications receiving 9472 citations.
Papers
More filters
Journal ArticleDOI
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini,Elza Muscelli,Silvia Frascerra,Simona Baldi,Andrea Mari,Tim Heise,Uli C. Broedl,Hans-Juergen Woerle +7 more
TL;DR: In patients with type 2 diabetes, empagliflozin-induced glycosuria improved β cell function and insulin sensitivity, despite the fall in insulin secretion and tissue glucose disposal and the rise in EGP after one dose, thereby lowering fasting and postprandial glycemia.
Journal ArticleDOI
Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes
Tim Heise,Leszek Nosek,Birgitte Biilmann Rønn,Lars Endahl,Lutz Heinemann,Christoph Kapitza,Eberhard Draeger +6 more
TL;DR: The results suggest that insulin detemir has a significantly more predictable glucose-lowering effect than both NPH insulin and insulin glargine in people with type 1 diabetes.
Journal ArticleDOI
Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
Marcus Lind,William H. Polonsky,Irl B. Hirsch,Tim Heise,Jan Bolinder,Sofia Dahlqvist,Erik Schwarz,Arndís F. Ólafsdóttir,Anders Frid,Hans Wedel,Elsa Ahlén,Thomas Nyström,Jarl Hellman +12 more
TL;DR: Among patients with inadequately controlled type 1 diabetes treated with multiple daily insulin injections, the use of continuous glucose monitoring compared with conventional treatment for 26 weeks resulted in lower HbA1c.
Journal ArticleDOI
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini,Simona Baldi,Silvia Frascerra,Brenno Astiarraga,Tim Heise,Roberto Bizzotto,Andrea Mari,Thomas R. Pieber,Elza Muscelli +8 more
TL;DR: It is concluded that by shunting substantial amounts of carbohydrate into urine, SGLT2-mediated glycosuria results in a progressive shift in fuel utilization toward fatty substrates.
Journal ArticleDOI
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
TL;DR: The pharmacodynamic variability of IDeg and insulin glargine under steady‐state conditions was compared and it was found that the former is more stable than the latter under steady-state conditions.